Ziopharm Oncology (ZIOP) Updates on Ad-RTS-hIL-12 Phase 1 in r/p GBM; Says One Death Deemed Unrelated to Study, Will Report to FDA (XON)
Tweet Send to a Friend
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
